<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77211">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01865045</url>
  </required_header>
  <id_info>
    <org_study_id>ONC/OSS-02/2012</org_study_id>
    <nct_id>NCT01865045</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients</brief_title>
  <official_title>Pharmacogenetics of Vinorelbine in Malignant Pleural Mesothelioma Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armando Santoro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter retrospective analysis .The aim of the present study is to investigate
      the molecular predictors of vinorelbine response in tumor samples of a series of MPM
      patients and evaluate  the possible impact on clinical outcome.

      Sample size: around 150 patients based on the availability of tumor size
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vinorelbine has recently become an alternative option for palliation in selected
      pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM). However, nowadays
      there are no definitive data about vinorelbine predictors of response in MPM patients. The
      identification of molecular predictors of effective therapy is important for maximizing
      therapeutic efficacy and minimizing useless treatment in cancer patients.

      In oncology a pharmacogenetic approach to customize the chemotherapy treatment according to
      individual as well as tumour genetic characteristics represents a modern and intriguing
      challenge. Recent studies have suggested that the expression levels of class III β-tubulin
      (TUBB3) or BRCA1, are related to a survival benefit from vinorelbine chemotherapy among
      patients with advanced solid malignancies, especially non-small cell lung cancer.  There are
      no data about the predictive factors to vinorelbine in MPM patients. The identification of
      molecular predictors of effective therapy may allow in the future the development of better
      therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR.</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association  of expression of TUBB3 and BRCA1 with clinical outcome (response, survival) .</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <description>no treatment</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Malignant pleural mesothelioma patients treated with vinorelbine as a second or later line
        chemotherapy with at least an objective response evaluation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MPM patients treated with vinorelbine in the ≥ second line setting will be
             retrospectively analyzed

          -  Patients will be selected based on the availability of tumor tissue

        Exclusion Criteria:

          -  NA
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>armando santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armando Santoro, MD</last_name>
    <phone>+39 02 8224 4080</phone>
    <email>armando.santoro@cancercenter.humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Zucali, MD</last_name>
    <phone>+3902 8224 4061</phone>
    <email>paolo.zucali@cancercenter.humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <phone>+39 02 8224 4080</phone>
      <email>armando.santoro@cancercenter.humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Paolo Zucali, MD</last_name>
      <phone>+39 02 8224 4061</phone>
      <email>paolo.zucali@cancercenter.humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Paolo Zucali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Armando Santoro, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
